These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8785939)

  • 41. Animal pain and distress in vaccine testing in the United States.
    Stephens ML; Alvino GM; Branson JB
    Dev Biol (Basel); 2002; 111():213-6. PubMed ID: 12678244
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of in vivo and in vitro methods for determining unitage of diphtheria antitoxin in adsorbed diphtheria-tetanus (DT) and diphtheria-tetanus-pertussis (DTP) vaccines.
    Shinde YP; Jadhav SS
    Dev Biol Stand; 1996; 86():245-60. PubMed ID: 8785954
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
    Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
    Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The reduction of the use of challenge testing to provide evidence of efficacy in tests of immunological veterinary medicinal products (IVMPs).
    Webster CJ
    Dev Biol Stand; 1996; 86():103-9. PubMed ID: 8785938
    [No Abstract]   [Full Text] [Related]  

  • 45. Use of animal testing for evaluating glycoconjugate vaccine immunogenicity.
    Madore DV; Strong N; Eby R
    Dev Biol Stand; 1999; 101():49-56. PubMed ID: 10566775
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of the toxin-binding inhibition (ToBI) test for the estimation of the potency of the tetanus toxoïd component in vaccines.
    van der Gun J; Akkermans A; Hendriksen C; van de Donk H
    Dev Biol Stand; 1996; 86():199-206. PubMed ID: 8785949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. It's Time to Reconsider
    Balls M
    Altern Lab Anim; 2020 Jan; 48(1):40-46. PubMed ID: 32316753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Refinement of in vivo tests.
    Morton DB
    Dev Biol Stand; 1999; 101():187-93. PubMed ID: 10566792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Scientific uses of animals: harm-benefit analysis and complementary approaches to implementing the three Rs.
    Griffin G; Clark JM; Zurlo J; Ritskes-Hoitinga M
    Rev Sci Tech; 2014 Apr; 33(1):265-72. PubMed ID: 25000799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Collaborative study for the establishment of two European Pharmacopoeia Biological Reference Preparations for serological potency testing of tetanus vaccines for veterinary use.
    Lensing HH; Behr-Gross ME; Daas A; Spieser JM
    Dev Biol (Basel); 2002; 111():69-76. PubMed ID: 12678226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Russell and Burch's 3Rs then and now: the need for clarity in definition and purpose.
    Tannenbaum J; Bennett BT
    J Am Assoc Lab Anim Sci; 2015 Mar; 54(2):120-32. PubMed ID: 25836957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Requirements for valid alternative assays for testing of biological therapeutic agents.
    Sesardic D
    Dev Biol Stand; 1996; 86():311-8. PubMed ID: 8785962
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Developments on the implementation of the Three Rs in research and education.
    van Zutphen LF; van der Valk JB
    Toxicol In Vitro; 2001; 15(4-5):591-5. PubMed ID: 11566596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A scientific and animal welfare assessment of the OECD Health Effects Test Guidelines for the safety testing of chemicals under the European Union REACH system.
    Combes R; Gaunt I; Balls M
    Altern Lab Anim; 2006 Mar; 34 Suppl 1():77-122. PubMed ID: 16555961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative analysis of the revised Directive 2010/63/EU for the protection of laboratory animals with its predecessor 86/609/EEC - a t4 report.
    Hartung T
    ALTEX; 2010; 27(4):285-303. PubMed ID: 21240470
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Balls M
    Altern Lab Anim; 2022 Jan; 50(1):10-26. PubMed ID: 35311373
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Challenges and opportunities for the implementation of the Three Rs in Canadian vaccine quality control.
    Long ME; Griffin G
    Regul Toxicol Pharmacol; 2012 Aug; 63(3):418-25. PubMed ID: 22634245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. "I'm not going to make a song and dance about it...".
    Richmond J
    Altern Lab Anim; 2009 Dec; 37 Suppl 2():13-7. PubMed ID: 20105005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FRAME, animal experimentation and the Three Rs: past, present and future.
    Balls M
    Altern Lab Anim; 2009 Dec; 37 Suppl 2():1-6. PubMed ID: 20105003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Workshop overview: scientific and regulatory challenges for the reduction, refinement, and replacement of animals in toxicity testing.
    Purchase IF; Botham PA; Bruner LH; Flint OP; Frazier JM; Stokes WS
    Toxicol Sci; 1998 Jun; 43(2):86-101. PubMed ID: 9710950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.